Focus on Covid-19 does not distract the FDA
Non-Covid-19 medical device approvals tick up alongside the agency’s pandemic efforts.
Exact chases its dream with $1.7bn Thrive deal
Setting its sights on the screening setting, Exact aims to be a major liquid biopsy player.
Exact gatecrashes the liquid biopsy party
Preliminary data on its pan-cancer blood test appear surprisingly competitive.
With its liquid biopsy approval, Foundation Medicine takes on Guardant
The first pan-cancer approval might have gone to Guardant, but Roche’s subsidiary’s blood test appears to be able to find more markers.
How best to develop a liquid biopsy?
Natera’s cancer blood test is couture, but Guardant’s pret-a-porter offering might sell better.
2019 was all about execution for smaller device makers
New products and strategic execution buoyed mid and small-cap medtechs, while safety worries took down one former high-flier.
Veracyte’s nasal lung cancer test results raise questions
Amid the sea of lung cancer blood test developers, one company has nosed out a different approach.
